Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 511–520 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 511
- Medicine slug
- eletriptan
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 12
- Source count
- 11
- Agreement rate
- 0.909091
- Recorded readings
2.0 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3953ca6-3da6-4420-9eb5-a16b38372f4e (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine the median T max is 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a501dbd-3ea8-47e4-9fcb-07035b8c8c9e (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine, the median T max is 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:077134d1-427d-6235-e063-6394a90abcf6 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine the median Tmax is 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62dc12ce-4f19-41c6-9593-3cae29f04af1 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine the median T max is 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49686c51-bbd9-45f0-92b1-8ffa81612e35 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine the median T max is 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6dc0893-b845-4f96-e053-6294a90a856f (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine the median Tmax is 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20276f5c-f2d6-469f-9a1b-aa254a1db21c (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine the median T max is 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb5ea5df-4add-420d-88cb-6dabe116ca65 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine the median T max is 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d412c0d-c8bd-498d-b57c-6626fb33147a (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine the median T max is 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbcb13f-d1cb-82c1-e063-6394a90a7753 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine the median T max is 2.0 hours.
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0dfeb1f-f0f0-449a-81ae-2c8fdddcff10 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
In patients with moderate to severe migraine the median T max is 2 hours.
Projected row 512
- Medicine slug
- eletriptan
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
138 L
- Numeric value
- 138
- Unit
- L
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0dfeb1f-f0f0-449a-81ae-2c8fdddcff10 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution: The volume of distribution of eletriptan following IV administration is 138 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3953ca6-3da6-4420-9eb5-a16b38372f4e (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution: The volume of distribution of eletriptan following IV administration is 138L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a501dbd-3ea8-47e4-9fcb-07035b8c8c9e (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of eletriptan following IV administration is 138L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:077134d1-427d-6235-e063-6394a90abcf6 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution: The volume of distribution of eletriptan following IV administration is 138L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62dc12ce-4f19-41c6-9593-3cae29f04af1 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution: The volume of distribution of eletriptan following IV administration is 138L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49686c51-bbd9-45f0-92b1-8ffa81612e35 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution: The volume of distribution of eletriptan following IV administration is 138L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6dc0893-b845-4f96-e053-6294a90a856f (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution: The volume of distribution of eletriptan following IV administration is 138L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20276f5c-f2d6-469f-9a1b-aa254a1db21c (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of eletriptan following IV administration is 138L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb5ea5df-4add-420d-88cb-6dabe116ca65 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution: The volume of distribution of eletriptan following IV administration is 138L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d412c0d-c8bd-498d-b57c-6626fb33147a (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution : The volume of distribution of eletriptan following IV administration is 138L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bbcb13f-d1cb-82c1-e063-6394a90a7753 (opens source in a new tab)
Eletriptan label
Version not recorded · Effective date not recorded
Distribution: The volume of distribution of eletriptan following IV administration is 138L.
Projected row 513
- Medicine slug
- eltrombopag
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 8
- Source count
- 8
- Agreement rate
- 0.875
- Recorded readings
21 to 32 hours
- Numeric value
- 21
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed51e463-7a03-4858-bbd2-882ce4753d5a (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of eltrombopag is approximately 21 to 32 hours in healthy subjects and 26 to 35 hours in patients with ITP.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9af1e314-91ca-4ebc-ac12-f9fddc6d7902 (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of eltrombopag is approximately 21 to 32 hours in healthy subjects and 26 to 35 hours in patients with ITP.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5fd3114-56b8-3ae3-fb03-9820a26ca4c6 (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of eltrombopag is approximately 21 to 32 hours in healthy subjects and 26 to 35 hours in patients with ITP.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c97337c3-d758-40a3-a1ef-fd122f15e821 (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of eltrombopag is approximately 21 to 32 hours in healthy subjects and 26 to 35 hours in patients with ITP.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05acf38e-7870-4809-a045-fc38e66b1110 (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of eltrombopag is approximately 21 to 32 hours in healthy subjects and 26 to 35 hours in patients with ITP.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e913cd11-f5fb-4ebe-81c7-0c5626b52cfd (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of eltrombopag is approximately 21 to 32 hours in healthy subjects and 26 to 35 hours in patients with ITP.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4af8f855-f710-e96f-e063-6294a90abb46 (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of eltrombopag is approximately 21 to 32 hours in healthy subjects and 26 to 35 hours in patients with ITP.
21 hours
- Numeric value
- 21
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cfdd1fa-d687-41f9-a160-9491f0beac1e (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of eltrombopag is approximately 21 hours to 32 hours in healthy subjects and 26 hours to 35 hours in patients with ITP.
Projected row 514
- Medicine slug
- eltrombopag
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 8
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed51e463-7a03-4858-bbd2-882ce4753d5a (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
In vitro studies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9af1e314-91ca-4ebc-ac12-f9fddc6d7902 (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
In vitro studies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cfdd1fa-d687-41f9-a160-9491f0beac1e (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
In vitro studies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5fd3114-56b8-3ae3-fb03-9820a26ca4c6 (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
In vitro studies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c97337c3-d758-40a3-a1ef-fd122f15e821 (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
In vitro studies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05acf38e-7870-4809-a045-fc38e66b1110 (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
In vitro studies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e913cd11-f5fb-4ebe-81c7-0c5626b52cfd (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
In vitro studies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4af8f855-f710-e96f-e063-6294a90abb46 (opens source in a new tab)
Eltrombopag label
Version not recorded · Effective date not recorded
In vitro studies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%).
Projected row 515
- Medicine slug
- empagliflozin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
12.4 h
- Numeric value
- 12.4
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5777b8a8-ada6-4950-8548-43a1de11f075 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Elimination The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1782b947-4a72-4feb-a488-1469d9af82bd (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Elimination The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:942a82a4-cbbd-4e44-9965-8d03f767912b (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Elimination The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b41c77-0abb-40ee-8578-86a748d0e19e (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Elimination The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a77214ca-572e-485e-aae9-f7950187e5fb (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Elimination The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b6261f6-4bdc-462e-8af1-4064664c62f3 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Elimination The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59ed43d9-b4e0-72a2-e063-6394a90a327d (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Elimination The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faf3dd6a-9cd0-39c2-0d2e-232cb3f67565 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Elimination The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:334f1b3d-5670-6685-e063-6294a90a7e47 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Elimination The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis.
Projected row 516
- Medicine slug
- empagliflozin
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
86.2%
- Numeric value
- 86.2
- Unit
- %
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5777b8a8-ada6-4950-8548-43a1de11f075 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Following administration of an oral [ 14 C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1782b947-4a72-4feb-a488-1469d9af82bd (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Following administration of an oral [ 14 C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:942a82a4-cbbd-4e44-9965-8d03f767912b (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Following administration of an oral [ 14 C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b41c77-0abb-40ee-8578-86a748d0e19e (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Following administration of an oral [ 14 C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a77214ca-572e-485e-aae9-f7950187e5fb (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Following administration of an oral [ 14 C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b6261f6-4bdc-462e-8af1-4064664c62f3 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Following administration of an oral [ 14 C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59ed43d9-b4e0-72a2-e063-6394a90a327d (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Following administration of an oral [ 14 C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faf3dd6a-9cd0-39c2-0d2e-232cb3f67565 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Following administration of an oral [ 14 C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:334f1b3d-5670-6685-e063-6294a90a7e47 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Following administration of an oral [ 14 C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.
Projected row 517
- Medicine slug
- empagliflozin
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5777b8a8-ada6-4950-8548-43a1de11f075 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Absorption After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1782b947-4a72-4feb-a488-1469d9af82bd (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:942a82a4-cbbd-4e44-9965-8d03f767912b (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Absorption After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b41c77-0abb-40ee-8578-86a748d0e19e (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a77214ca-572e-485e-aae9-f7950187e5fb (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Absorption After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b6261f6-4bdc-462e-8af1-4064664c62f3 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59ed43d9-b4e0-72a2-e063-6394a90a327d (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Absorption After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faf3dd6a-9cd0-39c2-0d2e-232cb3f67565 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Absorption After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:334f1b3d-5670-6685-e063-6294a90a7e47 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Absorption After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose.
Projected row 518
- Medicine slug
- empagliflozin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
73.8 L
- Numeric value
- 73.8
- Unit
- L
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5777b8a8-ada6-4950-8548-43a1de11f075 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Distribution The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1782b947-4a72-4feb-a488-1469d9af82bd (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Distribution The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:942a82a4-cbbd-4e44-9965-8d03f767912b (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Distribution The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b41c77-0abb-40ee-8578-86a748d0e19e (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Distribution The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a77214ca-572e-485e-aae9-f7950187e5fb (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Distribution The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b6261f6-4bdc-462e-8af1-4064664c62f3 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Distribution The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59ed43d9-b4e0-72a2-e063-6394a90a327d (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Distribution The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faf3dd6a-9cd0-39c2-0d2e-232cb3f67565 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Distribution The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:334f1b3d-5670-6685-e063-6294a90a7e47 (opens source in a new tab)
Empagliflozin label
Version not recorded · Effective date not recorded
Distribution The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis.
Projected row 519
- Medicine slug
- emtricitabine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
80%
- Numeric value
- 80
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6599395-3944-44f9-97f2-e0424c6b6a1f (opens source in a new tab)
Emtricitabine label
Version not recorded · Effective date not recorded
The relative bioavailability of EMTRIVA oral solution was approximately 80% of EMTRIVA capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdfb7868-3eba-46e1-a286-ca40760fd98d (opens source in a new tab)
Emtricitabine label
Version not recorded · Effective date not recorded
The relative bioavailability of emtricitabine oral solution was approximately 80% of emtricitabine capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a229c922-58eb-4795-9219-6cebb1779e35 (opens source in a new tab)
Emtricitabine label
Version not recorded · Effective date not recorded
The relative bioavailability of emtricitabine oral solution was approximately 80% of emtricitabine capsules.
Projected row 520
- Medicine slug
- emtricitabine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
10 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6599395-3944-44f9-97f2-e0424c6b6a1f (opens source in a new tab)
Emtricitabine label
Version not recorded · Effective date not recorded
Elimination The plasma FTC half-life is approximately 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdfb7868-3eba-46e1-a286-ca40760fd98d (opens source in a new tab)
Emtricitabine label
Version not recorded · Effective date not recorded
Elimination The plasma FTC half-life is approximately 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a229c922-58eb-4795-9219-6cebb1779e35 (opens source in a new tab)
Emtricitabine label
Version not recorded · Effective date not recorded
Elimination The plasma FTC half-life is approximately 10 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=510Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.